The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
PE-22-28 is a synthetic 7-amino-acid peptide derived from the spadin family, designed to inhibit the TREK-1 potassium channel. Research focuses on antidepressant-like effects and cognitive enhancement through BDNF-mediated neuroplasticity in preclinical models.
Summary: Inhibits TREK-1 potassium channels to enhance serotonergic neurotransmission and rapidly upregulate BDNF, producing antidepressant and cognitive-enhancing effects. Mechanisms (reported/proposed across domains): Mood / antidepressant • Blocks TREK-1 (TWIK-Related K+ Channel 1), a background potassium channel whose deletion in mice produces a depression-resistant phenotype. • TREK-1...
Investigational - Preclinical Only
Dose: 100–500 mcg (estimated from preclinical data) · Route: Intranasal · Subcutaneous (SC) · Frequency: 1× daily · Duration: 2–4 weeks